Tehran University of Medical Sciences

Science Communicator Platform

Stay connected! Follow us on X network (Twitter):
Share this content! On (X network) By
Circulating Tumor Braf Mutation and Personalized Thyroid Cancer Treatment Publisher



Khatami F1 ; Larijani B2 ; Tavangar SM3
Authors
Show Affiliations
Authors Affiliations
  1. 1. Chronic Diseases Research Center, Endocrinology and Metabolism Population Sciences Institute, Tehran, Iran
  2. 2. Endocrinology and Metabolism Research Center, Endocrinology and Metabolism Clinical Sciences Institute, Tehran, Iran
  3. 3. Departments of Pathology, Doctor Shariati Hospital, Tehran University of Medical Sciences, Tehran, Iran

Source: Asian Pacific Journal of Cancer Prevention Published:2017


Abstract

[No abstract available]
Related Docs
View other Related Docs
1. Liquid Biopsy in Thyroid Cancer: New Insight, International Journal of Hematology-Oncology and Stem Cell Research (2018)
2. Liquid Biopsy As a Minimally Invasive Source of Thyroid Cancer Genetic and Epigenetic Alterations, International Journal of Molecular and Cellular Medicine (2019)
3. Circulating Tumor Dna (Ctdna) in the Era of Personalized Cancer Therapy, Journal of Diabetes and Metabolic Disorders (2018)
Experts (# of related papers)
View all Related Experts
Seyed Mohammad Tavangar (15)
Bagher Larijani (9)
Other Related Docs
4. Personalized Treatment Options for Thyroid Cancer: Current Perspectives, Pharmacogenomics and Personalized Medicine (2019)
5. Circulating Ctdna Methylation Quantification of Two Dna Methyl Transferases in Papillary Thyroid Carcinoma, Journal of Cellular Biochemistry (2019)
6. Thyroid Cancer Research at Endocrinology and Metabolism Research Institute (Emri): A Report of Scientific Activities Between 2005 and 2020, Journal of Diabetes and Metabolic Disorders (2021)
7. Genetic and Epigenetic of Medullary Thyroid Cancer, Iranian Biomedical Journal (2018)
8. Hypermethylated Rassf1 and Slc5a8 Promoters Alongside Brafv600e Mutation As Biomarkers for Papillary Thyroid Carcinoma, Journal of Cellular Physiology (2020)
9. Promoter Methylation of Four Tumor Suppressor Genes in Human Papillary Thyroid Carcinoma, Iranian Journal of Pathology (2019)
10. Oncometabolites As Biomarkers in Thyroid Cancer: A Systematic Review, Cancer Management and Research (2019)
11. An Optimized Crispr/Cas12a Assay to Facilitate the Braf V600e Mutation Detection, Journal of Clinical Laboratory Analysis (2024)
12. Genetic and Epigenetic Differences of Benign and Malignant Pheochromocytomas and Paragangliomas (Ppgls), Endocrine Regulations (2018)
13. Current Diagnostic Status of Pheochromocytomaand Future Perspective: A Mini Review, Iranian Journal of Pathology (2017)
14. Mir-17-92A-1 Cluster Host Gene: A Key Regulator in Colorectal Cancer Development and Progression, Clinical and Experimental Medicine (2024)
15. Liquid Biopsy: The Unique Test for Chasing the Genetics of Solid Tumors, Epigenetics Insights (2020)
16. A Review of Driver Genetic Alterations in Thyroid Cancers, Iranian Journal of Pathology (2018)
17. The Presence of Tumor Extrachomosomal Circular Dna (Ecdna) As a Component of Liquid Biopsy in Blood, Medical Hypotheses (2018)
18. Meta-Analysis of Promoter Methylation in Eight Tumor-Suppressor Genes and Its Association With the Risk of Thyroid Cancer, PLoS ONE (2017)